Zonegran (Zonisamide) for the Treatment

Zonegran (Zonisamide) for the Treatment

Zonegran (Zonisamide) is an anti-epileptic drug indicated for the treatment of partial seizures in adults with epilepsy with or without secondary generalisation.

Eisai received approval from Swissmedic for Zonegran, for treating partial seizures in adults with newly diagnosed epilepsy, in July 2013.The drug was originally discovered and developed by Dainippon Pharmaceutical (now Dainippon Sumitomo Pharma). Eisai has obtained co-development and marketing rights for Zonegran in Europe.

Zonegran was initially approved in Europe as an adjunctive therapy for the treatment of partial-onset seizures in March 2005. The drug was also approved by the US Food and Drug Administration (FDA) for the same indication in March 2000.

Epilepsy - symptoms and severity

Epilepsy is a neurologic disorder of the brain that affects people of all ages. It is characterised by frequent seizures caused by abnormal activity in the brain.

It is estimated that about 70,000 people in Switzerland are living with epilepsy. The condition affects about 50 million people worldwide, and every eight in 1,000 people in Europe.